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Abstract
Background: Patients with painful knee osteoarthritis (OA) demonstrate hyperalgesia and altered pain-modulatory
responses. While some prior work has demonstrated cross-sectional associations between laboratory and clinical
pain measures, it is unknown whether individual variability in quantitative sensory testing (QST) responses at
baseline can prospectively predict analgesic treatment responses.
Method: Patients with knee OA (n = 35) were compared on QST responses to a demographically-matched pain-free
control group (n = 39), after which patients completed a month-long treatment study of diclofenac sodium topical
gel (1 %), applied up to 4 times daily.
Results: OA patients demonstrated reduced pain thresholds at multiple anatomic sites, as well as reduced conditioned
pain modulation (CPM) and enhanced temporal summation of pain. The most pain-sensitive patients tended to report
the most intense and neuropathic OA pain. Following diclofenac treatment, the knee OA cohort showed a roughly
30 % improvement in pain, regardless of the presence or absence of neuropathic symptoms. Baseline CPM scores, an
index of endogenous pain-inhibitory capacity, were prospectively associated with treatment-related changes in clinical
pain. Specifically, participants with higher CPM at baseline (i.e., better functioning endogenous pain-inhibitory systems)
showed more reduction in pain at the end of treatment (p < .05).
Conclusions: These results support prior findings of amplified pain sensitivity and reduced pain-inhibition in OA
patients. Moreover, the moderate to strong associations between laboratory-based measures of pain sensitivity and
indices of clinical pain highlight the clinical relevance of QST in this sample. Finally, the prospective association
between CPM and diclofenac response suggests that QST-based phenotyping may have utility in explaining
inter-patient variability in long-term analgesic treatment outcomes.
Trial registration: ClinicalTrials.Gov Identifier: NCT01383954. Registered June 22, 2011.
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Background
Knee osteoarthritis (OA) is a highly prevalent cause of
persistent pain and disability throughout the world [1].
The pathophysiology of OA pain is complex, with con-
tributions of peripheral factors such as synovial inflam-
mation, as well as central and peripheral nervous system
sensitization. Individuals reporting persistent OA-related
pain are characterized by enhanced pain sensitivity on
quantitative sensory testing (QST), and amplified brain
responses to noxious stimuli [2, 3]. Similar to other chronic
pain conditions, there is broad inter-patient variability in
pain symptomatology, including neuropathic pain symp-
toms [4, 5]. Studies have found differing degrees of associ-
ation between radiographic changes and pain severity, but
it is generally accepted that factors other than radiographic
features affect pain levels [2, 6, 7]. Of note, numerous
pain researchers have theorized that differing degrees
of sensitization of central nociceptive circuits may ex-
plain why some patients are disabled by severe OA pain
and prominent neuropathic symptoms, while others
with similar radiographic features report minimal pain
and few functional difficulties [2, 3, 8].
QST refers to a set of psychophysical methods used to
quantify somatosensory function. It is based on measur-
ing responses to calibrated somatosensory stimuli and
represents an extension and refinement of the bedside
clinical examination [3, 8]. QST has been used for: diagnos-
ing sensory neuropathies, investigating pain mechanisms,
characterizing somatosensory profiles, and quantifying
individual differences in pain sensitivity [9]. In addition
to indices of pain sensitivity such as pain threshold,
many QST protocols also evaluate pain-modulatory
processes such as conditioned pain modulation (CPM)
and temporal summation of pain. These dynamic mea-
sures of pain-inhibitory and pain-facilitatory processes can
provide important information about the central nervous
system’s processing and modulation of pain-related infor-
mation [8, 9].
To date, a handful of cross-sectional QST studies in
knee OA patients report evidence of amplified pain
sensitivity at affected joint sites and at unaffected body
locations [10]. Moreover, several longitudinal reports
have indicated that disease-modifying treatments such
as joint replacement can reverse the observed sensitization
and “normalize” QST profiles [11, 12]. What is currently
unknown, however, is how inter-patient variability in pain
sensitivity and pain modulation might prospectively pre-
dict responses to analgesic treatments. This is an import-
ant area of ongoing work, but at present we are unaware
of any relevant studies with knee OA patients, though
there is increasing interest in this topic in OA [13, 14].
Diclofenac is an anti-inflammatory drug that inhibits
prostaglandins; it is frequently used in the treatment of
rheumatic disease [15, 16]. Non-steroidal anti-inflammatory
drugs (NSAIDs), including diclofenac, are considered
first line medication options for treating osteoarthritis
pain. For knee OA, a common pain treatment is with
oral or topical NSAIDS such as topical diclofenac gel
(Voltaren Gel®) [15, 16]. A recent meta-analysis showed
that topical diclofenac modestly but significantly improved
pain and function scores over 12 weeks in patients with
osteoarthritis of the knee [17]. We used QST to profile
pain responses among patients with knee OA, and investi-
gated the potential for pre-treatment QST responses to
predict diclofenac’s treatment effectiveness. Our primary
hypothesis was that diclofenac gel would improve knee
pain, and that baseline variability in QST-assessed indices
of hyperalgesia and pain modulation would predict the
magnitude of treatment-related changes in knee pain, as
has been observed for other treatments [18].
Methods
Design and participants
We first compared 35 knee OA patients to a
demographically-comparable group of 39 pain-free
controls using QST. This comparison was followed by
a 5-week, uncontrolled effectiveness study of diclofenac
gel in patients with knee OA (ClinicalTrials.Gov Identi-
fier: NCT01383954). Logistically, the study consisted of
3 in-person visits: a screening visit followed by a one-week
pain baseline assessment period using daily electronic
diary entries, QST testing at a baseline visit following the
week of electronic diary completion, and then a final end-
of-treatment visit after 4 weeks of diclofenac gel use. The
end-of-treatment visit included a QST session identical to
that performed at baseline. Eligible patients were 30–75
years old and had radiographically-confirmed knee OA of
Grade II or III. Potential participants were excluded for
[1]: a history of meniscal or ACL involvement [2], current
SNRI, tricyclic antidepressant, or anticonvulsant use [3],
advanced renal disease [4], aspirin or NSAID hypersen-
sitivity [5], congestive heart failure [6], a coagulation
disorder [7], a history of ulcers or GI bleeding, and [8]
pregnancy. Additionally, participants were required to
stop any oral or topical NSAIDS for 1 week prior to
enrollment.
Subjects were recruited by email advertising, web and
bulletin board announcements in Boston, MA. Controls
were demographically matched to the patient group, and
were subject to the same exclusion criteria, with the
additional criterion that controls were free from painful
osteoarthritis or other chronic pain conditions.
The study medication was diclofenac sodium topical
gel (1 %, Voltaren Gel®); consistent with the product la-
beling, subjects were instructed to apply the gel up to 4
times daily, using a total of no more than 32 g of diclofe-
nac gel per day. Compliance with gel application was
monitored using an electronic diary. Subjects were told
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to avoid bathing for 1 h after application and also to
avoid the sun when using the gel.
In total, 137 volunteers (85 with OA, and 52 healthy
adults) responded to advertisements. Of the initial 52
healthy adults, 39 expressed interest, were eligible, and
were enrolled. Of the initial 85 OA patients, 61 expressed
interest and were screened by phone. Out of these 61 in-
terested candidates, 9 participants were ruled out at the
screening visit for failing to meet eligibility criteria and
thus, 52 subjects were finally enrolled in the study. The
study was performed in accordance with the Declaration
of Helsinki, and all study procedures were approved by
the Brigham and Women’s Hospital Institutional Review
Board. Written informed consent was obtained from every
subject by study staff at the time of enrollment. Four sub-
jects withdrew from the study, and 13 participants failed
to provide adequate post-treatment pain rating data, and
were thus excluded from the statistical analysis. Therefore,
the final analytic sample included 35 OA patients.
Measures
Patients completed multiple validated self-report mea-
sures of pain and function:
Knee Injury and Osteoarthritis Outcomes Score (KOOS)
This is a widely-used and well-validated self-report scale
assessing activity-related knee OA pain [19]. Scores are
normalized from 0–100, with higher scores indicative of
less pain and better functioning.
Neuropathic pain
Participants rated the presence and intensity of 3 hallmark
descriptors of neuropathic pain: burning pain, shooting
pain, and sensitivity to touch [20, 21]. These items were
rated from 0 = never to 100 = worst pain imaginable.
Electronic diaries
Patients monitored daily pain intensity, KOOS ratings of
activity-related pain, and neuropathic symptoms, with
Hewlett Packard © IPAQ electronic diaries [22]. Initial
daily ratings were made before the first gel application;
then, participants were prompted to rate their pain prior
to as well as 30, 60, 120, and 240 min following their
first gel application of the day. The initial daily rating
and the pain ratings prior to each application were aver-
aged within days and across days, providing weekly aver-
age pain intensity scores that reflected the mean pain
intensity prior to gel applications.
Quantitative sensory testing
For QST visits, participants refrained from intense phys-
ical exercise, using nicotine, or using the diclofenac gel
for at least 4 h prior to testing. Clinical pain ratings (on
a 0–100 scale) and verbal ratings of anxiety (on a 0–100
scale, with “no anxiety” and “severe anxiety” as the re-
spective anchors) were obtained at several points during
QST. During the roughly 45-min session, subjects were
seated comfortably in a reclining chair.
Mechanical pain thresholds were assessed using a
digital pressure algometer (Somedic; Sollentuna, Sweden).
Pressure pain thresholds (PPThs) were determined twice,
bilaterally at the trapezius muscle, the patella, and the
metacarpophalangeal joint of the thumb. At each site,
mechanical force was applied using a 0.5 cm2 probe cov-
ered with polypropylene pressure-transducing material;
pressure was increased at a steady rate of 30 kPA/s until
the subject indicated that the pressure was “first perceived
as painful”.
Participants then underwent an assessment of mechan-
ical temporal summation using weighted pinprick stimula-
tors, as in several previous studies [23]. The lowest-force
stimulator that produced a sensation of pain (128 or 256
mN for most subjects) was used to apply a train of 10
stimuli to the skin on the dorsum of the hand at the rate
of 1 per second. Participants rated the painfulness of the
first, fifth, and tenth stimulus, and also rated any ongoing
pain after-sensations 15 s following the final stimulus.
Response to deep pressure pain was ascertained via cuff
pressure algometry (CPA). Tonic, deep-tissue, mechanical
stimulation was applied using a Hokanson rapid cuff infla-
tor; a standard blood pressure cuff was wrapped comfort-
ably around the gastrocnemius muscle, and pressure was
increased at approximately 5 mmHg/s. Participants indi-
cated when the pressure was “first perceived as painful”.
Finally, responses to noxious cold were evaluated using
a repeated cold pressor task (CPT), involving immersion
of the right hand in 4 °C circulating water. Participants
underwent 3 CPTs, with the first 2 consisting of immersions
of the right hand for 30 s, with 2 min between immersions.
The 3rd and final CPT involved an immersion of the right
hand lasting until a participant reached pain tolerance (or a
3 min maximum). Participants rated the maximum intensity
of the cold pain on a 0–100 scale (“no pain” to “most in-
tense pain imaginable”) at the conclusion of each CPT.
During the first 2 cold pressor tasks, we also assessed
conditioned pain modulation (CPM), a non-invasive test
of endogenous pain-inhibitory systems using a hetero-
topic noxious conditioning stimulation paradigm [24].
During the CPT, PPTh was assessed on the contralateral
trapezius. CPM was quantified as percent change in
PPTh during the CPT relative to baseline PPT. Cold
pain intensity ratings (0–100) were also obtained at 30 s
intervals following each CPT in order to quantify painful
after-sensations.
Shuttle Walking Test (SWT)
The SWT is a physical function task assessing how rap-
idly the patient can walk for 25 ft from a starting point
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and back. Patients were timed with a stopwatch and two
runs were averaged. The SWT has shown good validity
and reliability as an objective outcome measure of phys-
ical functioning [25].
Data analysis
We compared OA patients to controls using independent
group t-tests. Within the OA group, associations between
QST responses and clinical pain outcomes were assessed
using Pearson correlations. Repeated measures Analysis of
Variance (ANOVA) was utilized to evaluate changes in
pain outcomes. Associations between QST responses and
changes in pain were assessed using Pearson correlations,
with follow-up regression analysis in which baseline pain
and demographic variables were controlled. Data were an-
alyzed using SPSS 21 (IBM software, Chicago). Subjects
with OA had to have completed at least 50 % of the study
(i.e., at least 2 weeks of drug treatment) in order to be in-
cluded in the statistical analysis.
Results
The groups were well-matched for demographic charac-
teristics such as gender (knee OA group = 64 % women,
control group = 67 % women) and age (patient age =
57.9 ± 10.7, control age = 59.8 ± 8.9). The controls were
pain-free, while knee OA patients reported, on average,
mild pain during the QST session and moderate levels of
daily knee pain on the dairy and the KOOS (see Table 1
and Fig. 3). Consistent with prior results, the knee OA
group showed significantly lower pain thresholds at ana-
tomic locations near disease-affected sites (i.e., PPTh on
the knee), and unaffected sites (i.e., PPTh on the trapez-
ius) (p’s < .05). Tolerance for the cold pressor test was
substantially lower among knee OA patients, and ratings
of cold pain after-sensations were elevated (See Fig. 1)
compared to controls (p’s < .05). In addition, CPM was
lower in knee OA patients (See Table 1), while temporal
summation of mechanical pain was enhanced (See Fig. 2)
(p’s < .05).
We next examined, among patients, baseline relation-
ships between QST responses and clinical pain measures.
As expected, we observed moderate inter-correlations
among these clinical pain measures: average diary pain in-
tensity was correlated at r = −.61 with KOOS pain (higher
scores on the KOOS indicate less pain, which is why these
measures are negatively correlated), and at r = .65 with
neuropathic pain symptoms, while KOOS pain and
neuropathic pain symptoms were correlated at r = −.56
(all p’s < .001). Each pain scale was significantly corre-
lated with SWT (i.e., for each measure, more severe
pain is associated with longer walk times) at p < .05,
with a mean correlation of r = .41. Overall, there were
many significant relationships between QST responses
and clinical measures (see Table 2). For example, cuff
pain threshold on the gastrocnemius was significantly
correlated (p’s < .01) with each measure of pain or func-
tion, with correlation coefficients of around .5, indicat-
ing roughly 25 % shared variance between mechanical
pain sensitivity and the severity of OA pain and phys-
ical dysfunction.
Treatment-Related Changes in Pain Responses
Electronic diary monitoring was used to track the fre-
quency of gel application; on average the cohort used
the gel 3.4 times ± .6 per day. Repeated measures Ana-
lysis of Variance (ANOVA) indicated that each of the
three clinical pain measures declined significantly over
time: daily diary pain intensity F (1, 29) = 25.7, p < .001,
KOOS activity-related pain F (1, 29) = 6.1, p < .05 and
neuropathic symptoms F (1, 29) = 4.9, p < .05 (See Fig. 3).
QST responses were highly stable over time, with no
changes, on average, from baseline to the final week of
treatment (all p’s > .2). In order to reduce the number of
analyses, we converted QST values to standard scores
[26] and averaged the 3 values for PPTh (assessed at the
thumb, trapezius, and knee) and the 3 cold pain variables
(maximum cold pain rating, cold pain after-sensations,
and cold pain tolerance, which was reverse-scored). Indi-
vidual standard scores were used for cuff pain threshold,
temporal summation, and CPM. Of the QST variables,
only CPM was significantly associated with treatment re-
sponse. CPM was negatively correlated with change in
diary pain intensity (r = −.38, p < .05), positively correlated
with change in KOOS (r = .45, p < .01) and negatively
correlated with change in neuropathic pain symptoms
(r = −.40, p < .05). In each case, higher baseline CPM
scores were associated with more pain reduction at the
Table 1 Comparison of psychophysical responses among knee
OA patients (n = 35) and pain-free controls (n = 39)
Knee OA (n = 35) Controls (n = 39)
Variables of Interest Assessed During the QST Session
Current Clinical Pain (0–100) 34.3 ± 26.2** 0 ± 0
Anxiety during QST (0–100) 23.1 ± 20.7 ** 5.5 ± 7.1
Mechanical and Cold Pressor Responses
PPTh (KPa)- Trapezius 275.1 ± 142.3* 346.4 ± 130.0
PPTh (KPa)- Thumb 227.5 ± 91.0** 339.9 ± 94.6
PPTh (KPa)- Knee 315.9 ± 158.0** 510.2 ± 188.6
Cuff Pain Threshold (mmHg) 129.3 ± 51.4* 168.6 ± 76.1
Cold Pain Tolerance (sec) 29.7 ± 30.8** 72.3 ± 60.5
Maximum Cold Pain (0–100) 75.9 ± 21.7 73.8 ± 22.2
CPM Index 118.7 ± 36.8* 142.5 ± 28.6
Other Mechanical and Cold Pressor Data Appear in Figs. 1 and 2
QST quantitative sensory testing, PPTh pressure pain threshold, KPa
Kilopascales, CPM conditioned pain modulation
*p < 0.05 for the group comparison
**p < 0.01 for the group comparison
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end of treatment. We followed up these significant
correlational results with linear regression analyses in
which baseline CPM was examined as a predictor of
end-of-treatment pain after controlling for baseline
pain scores as well as age and gender. In the case of
KOOS activity-related pain and electronic diary-reported
daily pain intensity, baseline CPM was a significant unique
predictor of end-of-treatment outcomes (See Table 3).
Discussion
The pathophysiology of OA pain is complex, with sig-
nificant inter-individual variability in symptomatology
that is unaccounted for by variation in radiographically-
assessed joint damage or other traditional OA pain
“mechanisms.” What is clear, however, is that central
nervous system processes characterized by sensitization
and maladaptive changes in endogenous pain modulation
play a significant role in shaping clinical pain symptoms
(2;3;8). A recent meta-analysis included 23 case-control
studies (comparing OA patients to controls) with over
1,000 total subjects [27]. The authors concluded that pain
thresholds were reduced in OA patients compared to con-
trols in affected anatomic sites (e.g., the knee), distal sites
adjacent to painful body locations, and also at remote
sites. The authors attributed these findings to “spreading
sensitization” or “central sensitization”, and suggested that
QST should be used to phenotype OA patients into sub-
groups which might differ in treatment response.
The present study extends these findings by examining
the capacity of dynamic QST phenotypes to predict re-
sponsiveness to a commonly-applied treatment. Com-
pared to controls, the knee OA group demonstrated
mechanical hyperalgesia in the form of reduced pain
thresholds at affected sites such as the knee, distal sites
Fig. 1 Cold pain ratings during and after cold pressor testing (data presented as means ± SEM). * Groups differ significantly at p < .05
Fig. 2 Pain ratings (0–100) for repetitive punctuate mechanical stimuli (data presented as means ± SEM). * Groups differ significantly at p < .05
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such as leg muscles, and unaffected sites such as the
trapezius. Indices of endogenous pain-modulatory pro-
cesses also suggested potential decrements in pain in-
hibition. The prolongation of painful after-sensations,
amplified temporal summation, and reduced CPM may
indicate a relative predominance of facilitation over inhib-
ition in central pain processing in knee OA patients [10].
Whether such group differences in pain-modulatory pro-
cesses represent pre-existing risk factors that contribute to
the development of chronic OA pain, or whether they are
the consequence of chronic pain, is currently unknown.
However, multiple prospective studies have now reported
that successful joint replacement surgery is associated with
“normalization” (e.g., improved CPM) of QST findings
post-operatively [11, 12].
Measures of pain threshold and pain modulation
were cross-sectionally related to individual variation in
patient-reported OA pain. These associations indicated
that the most pain-sensitive patients (i.e., those with
the lowest pain thresholds), the patients with the great-
est pain-facilitatory processes (e.g., the most temporal
summation), and the least effective pain inhibition (i.e.,
the lowest CPM scores) tended to report the most
severe pain. Other researchers have noted similar find-
ings in OA patients [10, 28]. Such results highlight the
possibility that QST phenotyping will prove useful in
subgrouping patients across diagnostic categories.
Interestingly, neuropathic pain symptoms were quite
prevalent in this sample of knee OA patients, and these
symptoms were responsive to treatment with a peripheral-
acting, topical NSAID. The magnitude of these baseline
neuropathic symptoms did not predict treatment re-
sponse, though there were significant cross-sectional
correlations with some QST measures of pain sensitivity,
including a positive association with temporal summation
of mechanical pain.
Table 2 Correlations between QST measures and clinical pain at baseline among knee OA patients (n = 35)
QST Variables Mean Daily Pain Intensity Activity-Related KOOS Pain Neuropathic Pain Symptoms Shuttle Walk Time
PPTh- Trapezius -.40* .37* -.43** -.39*
PPTh- Thumb -.33* .37* -.30 -.32*
PPTh - Knee -.33* .30 -.45** -.42**
Cuff Pain Threshold -.49** .53** -.49** -.56**
Cold Pain Tolerance -.21 .14 -.22 -.32*
Maximum Cold Pain .33* -.13 .24 .16
CPM Index .10 -.10 .28 .08
Temporal Summation .27 -.19 .31* .24
Cold Pain After-Sensations .34* -.33* .39* .25
QST quantitative sensory testing, PPTh pressure pain threshold, KPa Kilopascales, CPM conditioned pain modulation
*p < 0.05 for the group comparison
**p < 0.01 for the group comparison
Fig. 3 Pre-treatment and end-of-treatment scores on clinical outcome measures (data presented as means ± SEM). * Post-treatment differs from
pre-treatment at p < .05
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Prior studies have hinted at the neurochemical systems
that may be involved in mediating CPM and temporal
summation [10, 29, 30]. CPM, a sensitive measure of
deficits in pain modulation in fibromyalgia and related
persistent pain disorders, appears to depend on systems
that interact with serotonergic and noradrenergic de-
scending inhibitory pathways [31]. Temporal summation,
an analog of central sensitization, represents an important
pathophysiological process that contributes to the devel-
opment and maintenance of pain states in a number of
clinical contexts. While the temporal summation of pain
involves processes at the spinal level, recent functional
neuroimaging studies have highlighted the clear contribu-
tion of supraspinal processes as well [32, 33]. Collectively,
the modulation of temporal summation appears to involve
the activity of descending pain-inhibitory systems, which
are known to play crucial roles in pain processing. In prior
studies, medications such as NMDA antagonists, GABA
agonists, and opioids have all been shown to reduce tem-
poral summation of pain [34, 35]. Thus, the amplification
of pain sensitivity in this sample of OA patients may
reflect the activity of multiple neuroanatomical and
neurochemical systems.
CPM may have an important prognostic role in forecast-
ing treatment outcomes, and a recent study suggested that
pre-treatment CPM scores predicted the analgesic efficacy
of duloxetine [36]. Interestingly, diabetic neuropathy pa-
tients expressing lower baseline CPM scores seem to re-
spond better to duloxetine. The authors noted that CPM
reflects the functioning of descending pain-inhibitory
pathways which utilize serotonin and norepinephrine.
Therefore, a SNRI should be most effective in patients
whose serotonergic and noradrenergic pain control systems
function poorly at baseline. A more recent placebo-
controlled trial of tapentadol, also in diabetic neur-
opathy patients, found that patients randomized to
tapentadol subsequently improved their CPM, and this
increase in CPM corresponded to the degree and temporal
course of patients’ reduction in their neuropathic pain
[37]. In our study, the knee OA patients demonstrating
the largest magnitude of CPM at baseline also reported
the most pain reduction during topical diclofenac treat-
ment. This dissociation (i.e., those with poor CPM re-
spond relatively better to an SNRI while those with better
CPM respond relatively better to a peripherally-acting
NSAID) highlights the potential utility of this sort of phe-
notyping in the process of treatment selection, as well as
in understanding the mechanisms of treatment response
and physiological characteristics of responders and non-
responders to treatment.
A number of limitations should be considered when
interpreting these findings. First, the sample size was
relatively small, which precludes us from evaluating the
unique predictive capacity of a broad set of factors. Sec-
ond, the present study design did not include a control
group, which prevents us from drawing definitive con-
clusions regarding the specific effects of NSAIDS on
pain in this sample. Third, the duration of the study was
rather short, limiting our analyses to the prediction of
acute treatment responses. In other settings, CPM has
been observed to predict longer-term outcomes such as
the development of chronic pain 6 months after a sur-
gery [31], and future studies of CPM’s predictive capacity
may benefit from longer follow-up periods. Finally, while
we did perform a multimodal QST assessment, we mea-
sured CPM in only one manner, and it is possible that
differing patterns of findings might have obtained when
using other methods.
Conclusions
Despite these limitations, this study supports the clinical
relevance of widespread hyperalgesia and maladaptive
pain modulation in OA patients. Moreover, these findings
are among the first to suggest that pre-treatment variation
in CPM may be a valuable predictor of responses to anal-
gesic treatments, regardless of the presence of neuropathic
pain symptoms. Future treatment studies in OA may
strongly benefit from baseline patient phenotyping using a
QST protocol that includes CPM assessment. Overall, the
findings of this study add to a small but promising body
of literature supporting the capacity of psychophysical
tests of pain modulation to provide useful, prospective,
treatment-relevant information.
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